Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Primary objective :
To evaluate the efficacy (in terms of change in HbA1c readings starting from baseline then
after 13 weeks & at the end of the study which will be after 26 weeks) in subjects with type
I diabetes mellitus.
Secondary objective :
- Recording the average daily dose of both insulin Glulisine & insulin Glargine in type I
DM.
- Recording adverse events.